Clinical Trial

The Safety and PK Study of Inhaled ICF004 in Healthy Chinese Volunteers

Study acronym: ICF004-INH
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the safety of an inhaled study drug called ICF004 in healthy adults. ICF004 is being created to treat progressive lung scarring in the future. It will also learn how the body handles the drug over time. The main questions it aims to answer are: What medical problems or side effects do participants have when taking ICF004? How does the body absorb and metabolize ICF004? Researchers will compare ICF004 to a placebo (a look-alike powder that contains no active drug) to see if ICF004 is safe and well-tolerated. Participants will: Breathe in a single dose or multiple doses of ICF004 or a placebo using a dry powder inhaler; Stay at or visit the study clinic for checkups and tests; Give blood samples so researchers can measure the amount of drug in their blood.
Trial Details
NCT Number NCT07719218
Lead Sponsor Ruijin Hospital
Conditions Interstitial Lung Disease (ILD), Healthy Volunteers
Enrollment 73 participants
Start Date 2026-07-30
Primary Completion 2029-07-30 (estimated)
Study Completion 2029-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22